NARA Discovery
Article Details
← Back to Search Results
Journal Article

Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases

Jorge Alvar; Fabiana Alves; Bruno Bucheton; Louise Burrows; Philippe Büscher; Eugenia Carrillo; Ingrid Felger; Marc P. Hübner; Javier Moreno; Maria-Jesus Pinazo; Isabela Ribeiro; Sergio Sosa-Estani; Sabine Specht; Antoine Tarral; Nathalie Strub Wourgaft; Graeme Bilbe
Seminars in Immunopathology · Vol. 42, Issue 3 · pp. 231-246 · 2020

Abstract

Progress has been made in the control or elimination of tropical diseases, with a significant reduction of incidence. However, there is a risk of re-emergence if the factors fueling transmission are not dealt with. Although it is essential to understand these underlying factors for each disease, asymptomatic carriers are a common element that may promote resurgence; their impact in terms of proportion in the population and role in transmission needs to be determined. In this paper, we review the current evidence on whether or not to treat asymptomatic carriers given the relevance of their role in the transmission of a specific disease, the efficacy and toxicity of existing drugs, the Public Health interest, and the benefit at an individual level, for example, in Chagas disease, to prevent irreversible organ damage. In the absence of other control tools such as vaccines, there is a need for safer drugs with good risk/benefit profiles in order to change the paradigm so that it addresses the complete infectious process beyond manifest disease to include treatment of non-symptomatic infected persons.

Bibliographic Information

JournalSeminars in Immunopathology
PublisherSpringer
Publication Date2020-06-01
Publication Year2020
Volume42
Issue3
Pages231-246
Document TypeJournal Article
eISSN1863-2300
DOI10.1007/s00281-020-00796-y

Access Information

NARA Access Coverage1978-01-01~Current
Journal Homepagehttps://www.springer.com/journal/281
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.